4DS MEMORY LIMITED — Director's Dealing 2020

Jul 28, 2020

Appendix 3Y Change of Director’s Interest Notice

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Introduced 30/9/2001.
Name of entity	4DS Memory Limited
ABN	43 145 590 110

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

irector for the purposes of section 205G of	the Corporations Act.
Name of Director	Mr David McAuliffe
Date of last notice	29 November 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct and Indirect	Direct and Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstancesgiving rise to the relevant interest.		Concept Biotech Pty Ltd (director related entity)David Jerimiah McAuliffe (trustee and beneficiary)Margaret Elizabeth Livingston (spouse)
Date of change		29 July 2020
No. of securities held prior tochange		DirectDavid McAuliffe2,767,740 fully paid ordinary sharesIndirectConcept Biotech Pty Ltd2,498,812 fully paid ordinary sharesDavid Jerimiah McAuliffe8,056,743 fully paid ordinary sharesMargaret Elizabeth Livingston7,000,000 unlisted options exercisable at $0.052 each on or before22 January 2024, with 1,250,000 subject to vesting conditions
Class		Fully paid ordinary	shares
Number acquired		Indirect – 333,333 Trust>)	(David Jerimiah McAuliffe<D9M Investment
Number disposed		-

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration	$15,000
includes brokerage/gst
Note: If consideration is non-cash, provide
details and estimated valuation
No. of securities held after	Direct
change	David McAuliffe
	2,767,740 fully paid ordinary shares
	Indirect
	Concept Biotech Pty Ltd
	2,498,812 fully paid ordinary shares
	David Jerimiah McAuliffe
	8,390,076 fully paid ordinary shares
	Margaret Elizabeth Livingston
	7,000,000 unlisted options exercisable at $0.052 each on or before
	22 January 2024, with 500,000 subject to vesting conditions
Nature of change	Take-up of entitlement pursuant to share purchase plan.
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

sclosed in this part.
Detail of contract	N/A-
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change	N/A

Part 3 –[+] Closed period

Part 3–+Closed period	Part 3–+Closed period
Were the interests in the straded during a+closed p
	Were the interests in the straded during a+closed p	curities or contracts deta	iled above	N/A
		eriod where prior written	clearance
	was required?
	If so, was prior written clea	rance provided to allow t	he trade to	N/A
	proceed during this period	?
	If prior written clearance w	as provided on what dat	e was this	N/A
	provided?	,

• See chapter 19 for defined terms.

Appendix 3Y Page 2